Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA.
J Pathol. 2012 Feb;226(3):413-20. doi: 10.1002/path.3967. Epub 2011 Dec 20.
It has been well established that ovarian low-grade and high-grade serous carcinomas are fundamentally different types of tumours. While the molecular genetic features of ovarian high-grade serous carcinomas are now well known, the pathogenesis of low-grade serous carcinomas, apart from the recognition of frequent somatic mutations involving KRAS and BRAF, is largely unknown. In order to comprehensively analyse somatic mutations in low-grade serous carcinomas, we applied exome sequencing to the DNA of eight samples of affinity-purified, low-grade, serous carcinomas. A remarkably small number of mutations were identified in seven of these tumours: a total of 70 somatic mutations in 64 genes. The eighth case displayed mixed serous and endometrioid features and a mutator phenotype with 783 somatic mutations, including a nonsense mutation in the mismatch repair gene, MSH2. We validated representative mutations in an additional nine low-grade serous carcinomas and 10 serous borderline tumours, the precursors of ovarian low-grade, serous carcinomas. Overall, the genes showing the most frequent mutations were BRAF and KRAS, occurring in 10 (38%) and 5 (19%) of 27 low-grade tumours, respectively. Except for a single case with a PIK3CA mutation, other mutations identified in the discovery set were not detected in the validation set of specimens. Our mutational analysis demonstrates that point mutations are much less common in low-grade serous tumours of the ovary than in other adult tumours, a finding with interesting scientific and clinical implications.
已经明确的是,卵巢低级别浆液性癌和高级别浆液性癌是两种完全不同的肿瘤类型。虽然高级别浆液性癌的分子遗传学特征现在已经众所周知,但除了认识到涉及 KRAS 和 BRAF 的频繁体细胞突变外,低级别浆液性癌的发病机制在很大程度上仍是未知的。为了全面分析低级别浆液性癌中的体细胞突变,我们对 8 个亲和纯化的低级别浆液性癌样本的 DNA 进行了外显子组测序。在其中的 7 个肿瘤中,只鉴定到数量非常少的突变:在 64 个基因中总共存在 70 个体细胞突变。第 8 个病例显示出混合性浆液性和子宫内膜样特征以及突变子表型,存在 783 个体细胞突变,包括错配修复基因 MSH2 的无义突变。我们在另外 9 个低级别浆液性癌和 10 个浆液性交界性肿瘤(卵巢低级别浆液性癌的前体)中验证了代表性突变。总的来说,最常发生突变的基因是 BRAF 和 KRAS,分别在 27 个低级别肿瘤中的 10 个(38%)和 5 个(19%)中发生。除了一个病例存在 PIK3CA 突变外,在发现集标本中鉴定到的其他突变在验证集标本中均未检测到。我们的突变分析表明,点突变在卵巢低级别浆液性肿瘤中比在其他成人肿瘤中要少见得多,这一发现具有有趣的科学和临床意义。